13th annual report the preeminent source for medical benefit drug trend

publications Spring 2024 Prime Therapeutics Report March 15, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 6)...

Managed Healthcare Executive

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Perspectives High-Cost Therapy Profile: April Detailed information about prademagene zamikeracel Topical surgical application Date High Cost Therapy Profile Gene therapy/Dermatology Prademagene...

Get the most value and best outcomes from C&GT Cell and gene therapies (C&GTs) represent breakthrough science, but often come at a high cost. Breadcrumb Home Our solutions Condition management Cell...

Perspectives High-Cost Therapy Profile: May Detailed information about Fidanacogene elaparvovec-dzkt Intravenous (IV) High Cost Therapy Profile Gene therapy/Hematology Fidanacogene elaparvovec-dzkt...

Breadcrumb Home Newsroom Custom Content Publications Drug Approvals Monthly Update: September 2024 PUBLICATIONS Drug Approvals Monthly Update: September 2024 This monthly update of United States...

Designed for unions, delivered with care At Prime Therapeutics (Prime), we built our model around transparency, flexibility and aligned incentives from the start. We don’t just help unions respond...

Read Drug Approvals Monthly Update: June 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...